✓ Clinically Audited: August 2026 • OncoGuides Medical Advisory Board

Pancreatic Cancer: Resectability Criteria, mFOLFIRINOX, Biomarkers & CA 19-9

Multidisciplinary management of resectable, borderline resectable, and metastatic pancreatic adenocarcinoma.

Anatomical Site / System Pancreas (Exocrine Acinar / Ductal Epithelium)

Staging System AJCC TNM 8th Edition & NCCN Resectability Criteria

Primary Biomarkers CA 19-9, Germline BRCA1/2, PALB2, KRAS (G12D/V/R/C), MSI-H/dMMR, NTRK fusions

Standard Guidelines NCCN, ASCO, ESMO 2026 Consensus

1. Overview & Pathophysiology

Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% of all malignant pancreatic neoplasms and is characterized by dense desmoplastic stroma, early micrometastatic dissemination, and high intrinsic chemoresistance. Resectability staging (Resectable vs Borderline Resectable vs Locally Advanced Unresectable vs Metastatic) based on high-resolution contrast-enhanced pancreatic-protocol CT is the crucial initial decision point.

2. Molecular Subtypes & Biomarker Profiling

Essential molecular and serum biomarkers in pancreatic oncology:

Serum CA 19-9: Carbohydrate antigen 19-9 is the primary tumor marker for monitoring treatment response and detecting recurrence. Non-secretors (Lewis blood group negative, ~10% of population) do not express CA 19-9.
Germline BRCA1, BRCA2, and PALB2: Present in 5–7% of patients; confers homologous recombination deficiency (HRD) and sensitivity to platinum-based chemotherapy (mFOLFIRINOX) and maintenance PARP inhibitor Olaparib (POLO trial).
KRAS Somatic Mutations: Mutated in >90% of tumors (predominantly G12D, G12V, G12R). Emergence of targeted KRAS inhibitors is expanding therapeutic options.
MSI-H / dMMR: Present in ~1% of PDAC; predicts dramatic and durable responses to Pembrolizumab immunotherapy.

3. Standard-of-Care Treatment Protocols (NCCN/ASCO 2026)

Disease Category	Primary Treatment Approach	Standard Systemic Regimen
Resectable / Borderline	Neoadjuvant mFOLFIRINOX or Gem/nab-Paclitaxel followed by Whipple procedure (Pancreaticoduodenectomy) or distal pancreatectomy	mFOLFIRINOX (Oxaliplatin, Irinotecan, Leucovorin, 5-FU) x 6 months total perioperative duration
Metastatic (Good Performance ECOG 0-1)	Systemic chemotherapy with disease response evaluation every 8–12 weeks	mFOLFIRINOX or NALIRIFOX (Liposomal Irinotecan, 5-FU/LV, Oxaliplatin) or Gemcitabine + nab-Paclitaxel
Metastatic with Germline BRCA/PALB2	Platinum-sensitive disease post >= 16 weeks first-line platinum	Maintenance Olaparib (Lynparza) 300 mg BID orally

4. Supportive Oncology & Organ Comorbidities

Multidisciplinary Supportive Care Links:

Managing therapy-induced organ toxicities is essential for maintaining dose intensity and overall survival:

Cardiotoxicity & LVEF Monitoring: CardioOncoGuides (Anthracycline & HER2-induced cardiomyopathy).
Renal Function & Cisplatin AKI: NephroOncoGuides (GFR calculators, TLS & hydration protocols).
Pulmonary Toxicity & Pneumonitis: PulmonaryOncoGuides (ICI pneumonitis steroid tapers & Bleomycin DLCO).
Cutaneous Toxicities & EGFR Rash: OncoDermatologyGuides (SCORTEN calculators, doxycycline tapers & scalp cooling).
Chemotherapy Neuropathy (CIPN): NeuroOncoGuides (Duloxetine titration & cryotherapy).
Cancer-Related Lymphedema: LymphedemaOncoGuides (Complete Decongestive Therapy CDT).
Fertility Preservation: OncoFertilityGuides (Oocyte/sperm cryopreservation & GnRH-a).
Psychosocial Support: PsychoOncoGuides (Distress Thermometer & free psychotherapy grants).

5. Patient & Caregiver Frequently Asked Questions

Why is universal germline testing recommended for all pancreatic cancer patients?

National guidelines recommend universal germline genetic testing (including BRCA1/2, PALB2, Lynch syndrome genes) for all patients diagnosed with pancreatic adenocarcinoma, regardless of family history, because identifying homologous recombination deficiency directly guides treatment with platinum agents and PARP inhibitors.

6. Primary Evidence & Guideline Citations

Tempero MA, Malafa MP, Al-Hawary M, et al. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2026. J Natl Compr Canc Netw. PMID: 33798973.
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (PRODIGE 24). N Engl J Med. 2018;379(25):2395-2406. PMID: 30575634.
Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (POLO). N Engl J Med. 2019;381(4):317-327. PMID: 31157963.